New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Form SC 13D/A Berkshire Grey, Inc. Filed by: New Enterprise Associates 15, L.P.
-
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
-
Harvard China Forum 2023 Includes Yida Gao of Shima Capital
-
Shima Capital Founder Yida Gao Teaching Crypto Finance Course at MIT
-
Shima Capital's Founder Yida Gao Teaches Crypto Finance Course at MIT
-
Form SC 13D/A Adaptimmune Therapeutics Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Perplexity AI Launches iOS Version of Conversational Answer Engine, Announces $25.6M Series A Round Led by NEA
-
First Annual Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers
-
Gilead Sciences (GILD) and Pionyr Immunotherapeutics Change Exclusive Option Agreement
-
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
-
Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results
-
FIRE1 Raises $25 Million to Revolutionize Heart Failure Home Monitoring
-
Topia Celebrates Transformational Year with Strong Customer Growth & New Solutions to Help Companies Manage Dynamic Workforce Mobility
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
-
Topia Awarded New Patent for Machine Learning Models to Identify and Use Seasonality Trend Data
-
AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
-
Form SC 13D/A MINERVA SURGICAL INC Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Stablix to Present at Wells Fargo 2023 Targeted Protein Degradation Summit
-
HEAVY.AI Teams with Bain, Maxar, and NVIDIA to Provide High-Fidelity Digital Twins for Telecom Networks
-
Form SC 13D/A GLYCOMIMETICS INC Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Minerva Surgical Closes $30 Million Private Placement of Common Stock
-
Fabric8Labs Closes $50M Series B Financing for Electrochemical Additive Manufacturing Technology
-
flox Raises $27 Million, Introduces Open Source Platform to Bring Nix to Everyone
-
Form SC 13G/A Tuya Inc. Filed by: New Enterprise Associates 14, L.P.
-
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
-
AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors
-
Stride Health Recognized As One of Built In's Best Places to Work in 2023
-
NEA Closes On Two Funds Totaling $6.2 Billion
-
Form SC 13D/A Arcellx, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A MINERVA SURGICAL INC Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
-
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
-
U.S. startup Outrider raises $73 million to scale up autonomous yard trucks
-
Outrider raises $73 million Series C financing to accelerate the adoption of autonomous distribution yard operations
-
Stablix Appoints Douglas Williams, Ph.D., to Board of Directors
-
BMO Receives Regulatory Approval to Acquire Bank of the West
-
New Feature From Topia Allows HR And Global Mobility Professionals To Better Manage Group, Project Team And Bulk Moves
-
Form SC 13D/A Oyster Point Pharma, Filed by: New Enterprise Associates 14, L.P.
-
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
GoodLeap Forms Advisory Council with Diverse Leadership and Expertise
-
Minerva Surgical (UTRS) Prices 146.63M Share Private Placement at $0.205/sh
-
Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners
-
Form 4 Arcellx, Inc. For: Dec 20 Filed by: New Enterprise Associates 15, L.P.
-
Atara Biotherapeutics Announces Changes to Its Board of Directors
-
Form SC 13D/A Eargo, Inc. Filed by: New Enterprise Associates 15, L.P.

